title: Targeting nerve growth factor in pain: what is the therapeutic potential?
abstract: Chronic pain presents a huge economic and social burden, with existing treatments largely unable to satisfy medical needs. Recently, studies have shown that nerve growth factor (NGF) is a major mediator of inflammatory and neuropathic pain, providing a new therapeutic target. Although originally discovered as a trophic factor for sympathetic and sensory neurons during development, it now appears that in adults, levels of NGF are elevated in many acute and chronic pain conditions. Furthermore, preclinical animal models of inflammatory and neuropathic pain also show increased NGF levels, while the sequestration of NGF alleviates the associated hyperalgesia. The molecular mechanisms involved are being elucidated. This review briefly examines pain signaling pathways and describes currently available analgesics. It then investigates the approaches taken in targeting NGF-mediated pain. Current options being explored include the development of humanized monoclonal antibodies to NGF or its tyrosine kinase receptor TrkA (also known as neurotrophic tyrosine kinase receptor, type 1 [NTRK1]), and the sequestration of NGF using TrkA domain 5 (TrkAd5), a soluble receptor protein that binds NGF with picomolar affinity. Administration of either antibodies or TrkAd5 has been shown to be effective in a number of preclinical models of pain, including cystitis, osteoarthritis, UV irradiation (sunburn), and skeletal bone pain due to fracture or cancer. Other possible future therapies examined in this review include small-molecule TrkA antagonists, which target either the extracellular NGF binding domain of TrkA or its intracellular tyrosine kinase domain.
authors.affiliation: University of Bristol, Bristol, UK.
authors.forename: Judy J
authors.initials: JJ
authors.lastname: Watson
authors.forename: Shelley J
authors.initials: SJ
authors.lastname: Allen
authors.forename: David
authors.initials: D
authors.lastname: Dawbarn
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D010146:Pain / Q000503:physiopathology; D059408:Pain Management; D010455:Peptides / Q000627:therapeutic use; D020917:Receptor, trkA / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000276:immunology / Q000502:physiology; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D000700:Analgesics; D000911:Antibodies, Monoclonal; D010455:Peptides; D011994:Recombinant Proteins; C498075:tyrosine receptor kinase A Ig2; D020932:Nerve Growth Factor; D020917:Receptor, trkA